Navigation Links
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

VIENNA, Oct. 21 /PRNewswire/ -- Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

Intercell's vaccine candidate has demonstrated a sustained reduction of viral load in chronic Hepatitis C (CHC) patients in a Phase II proof-of-concept trial. Nitazoxanide is an oral therapy that targets host cell factors involved in HCV replication and is not associated with viral mutations conferring resistance. Nitazoxanide has been shown to induce sustained virologic response as monotherapy in some patients chronically infected with HCV.

The planned European Phase II trial will include about 60 treatment-naïve patients chronically infected with HCV genotype-1 in three treatment arms: (1) IC41 plus nitazoxanide, (2) IC41 plus nitazoxanide and Pegasys® (peginterferon alfa-2a) and (3) Pegasys and Copegus® (ribavirin), the current standard of care, as an active control. The primary endpoint will be sustained virologic response (no detectable HCV RNA 24 weeks after end-of-treatment).

The companies involved in the combination study will retain commercial rights for their respective products.

"We are very pleased about this important next step in the development of our vaccine candidate against Hepatitis C. The distinctly different mode-of-action and the outstanding tolerability of both treatments create a joint approach in a field that will continue to have high unmet medical need over the next decades," stated Gerd Zettlmeissl, CEO of Intercell.

"We are excited about this novel therapeutic approach for chronic Hepatitis C," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark. "There is an important need for novel therapies that offer improvements in safety and efficacy com
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
2. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
3. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
4. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
8. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
11. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and KISSING, Germany , ... distributor of a single use and computer-assisted ("robotic") colonoscopy ... Shamir , a worldwide recognized medical device executive, as ... Mr. Shamir is a highly respected global visionary ... assignment he served as President and Chief Executive Officer ...
(Date:7/30/2014)... and SAN DIEGO , July 30, ... ARNA ) announced today that an article based on ... lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, and ... recently published in the online issue of Obesity , ... objective of these analyses was to identify whether there is ...
(Date:7/30/2014)... FOREST, Ill., July 30, 2014  Hospira, Inc. ... provider of injectable drugs and infusion technologies, today ... 30, 2014. Net sales for the quarter were ... were $0.72. (Adjusted* measures exclude specified items as ... attached schedules.) On a U.S. Generally Accepted Accounting ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28
... HEIGHTS, Mich. , April 30 The Editorial Advisory and ... Pharmaceutical Industries Limited (Nasdaq: TEVA ) as its July ... GILD ) as its July "Undervalued Stock" for investors, informational and ... "The committee ...
... 30 US Oncology, Inc., the nation,s ... of US Oncology affiliated scientists from the US Oncology ... pharmaceutical companies on April 24 - 25 , at ... for the Fifth Annual Cancer Drug Development Working Group. These ...
Cached Medicine Technology:BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 2BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 3US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow 2US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow 3US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow 4US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow 5
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark have ... massive distribution of Truth About Drugs education ... Strøget, the famous Copenhagen walking street. Popular with ... ambiance, some quarter of a million people stroll down ... These activities are part of a coordinating effort by ...
(Date:7/30/2014)... 2014 The family of a Vermont ... a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his ... LLP reports. According to the complaint, which was filed ... on July 25th, the decedent had been taking Xarelto ... brain bleed that ultimately led to his death on ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 DRE Medical ... to announce the launch of its Medical Trade ... resource for medical professionals and equipment vendors. , The ... and conventions in the United States and around the ... calendar, and that number is always growing. , Information ...
(Date:7/30/2014)... Atlanta, Georgia (PRWEB) July 30, 2014 ... Business and Technology Alliance of TAG (B&TA), today issued ... 2014 TAG Excalibur Awards. , Interested companies have until ... program after which, Semi-Finalists will be selected by the ... be required to meet with the judges for interviewing ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3
... with Chronic Lung Disease to ... ... Technologies Inc. (SeQual),announced today the launch of "Mark,s Breathe Easy Tour," ... Seton Medical Center intended to raise,awareness of chronic lung disease, such ...
... of,directors for Hillenbrand, Inc. (NYSE: HI ) has ... company,s outstanding common shares. Purchases,will be made from time ... transactions, and will be funded from the company,s available,cash ... a share repurchase program for our,new company reflects its ...
... be significant, experts say , , THURSDAY, July 24 (HealthDay ... Grove Retirement Village in Sandy Spring, Md., some of the ... cat along. , The woman, in the early stages of ... assisted living administrator at Brooke Grove, a center specializing in ...
... 24 Tepha, Inc., a developer of,medical devices ... announced,today that it has appointed John Hartnett to ... Operating Officer. Mr. Hartnett joins Tepha,following an eighteen ... from field sales, to marketing management, and, most ...
... Users to Create a Book on CaringBridge Sites Documenting ... Their Journey Through Treatment or ... nonprofit Web,service that connects families and friends when someone ... provides users with the,ability to preserve their personal Web ...
... July 24 Clear Catheter,Systems (http://www.clearcatheter.com ), ... a proprietary medical catheter clearance,platform, today announced the ... led by X Gen Ltd, a family venture ... grant from the Cleveland Clinic Global,Cardiovascular Innovation Center ...
Cached Medicine News:Health News:SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride 2Health News:SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride 3Health News:SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride 4Health News:Hillenbrand, Inc. Board of Directors Approves $100M Share Repurchase Program 2Health News:Pet Doors Opening at Assisted Living Centers 2Health News:Pet Doors Opening at Assisted Living Centers 3Health News:Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer 2Health News:CaringBridge(R) Enhances Web Service by Adding Printable CaringBook Option 2Health News:CaringBridge(R) Enhances Web Service by Adding Printable CaringBook Option 3Health News:Clear Catheter Systems Completes $600-Million Financing, Opens Cleveland Office 2
... Courier* controls and monitors the movement of ... refrigerators. BloodTrack Courier provides a complete audit ... network. , BloodTrack Courier electronically records a ... from its receipt of blood products through ...
Lasts up to 3 months , Absorbable copolymer of glycolic acid and trimethylene carbonate , Designed to provide relief from short term dry eye conditions. , Appropriate for surgery-related d...
... Multifocal are the only contact lenses designed ... those with aging eyes: presbyopia and eye ... a superior lens design, Balanced Progressive Technology, ... our patented PC Technology. The result? Lenses ...
... Accommodating Intraocular Lens is for the treatment of ... many middle aged and older patients. , Presbyopia ... the natural lens of the eye as a ... elastic. With less elasticity, the eye has a ...
Medicine Products: